JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Glaukos Corp

Gesloten

SectorGezondheidszorg

88.18 0.79

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

84.44

Max

89.28

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

-18M

Verkoop

1.2M

107M

Winstmarge

-17.012

Werknemers

995

EBITDA

1.6M

-21M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+45.98% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

69M

5.4B

Vorige openingsprijs

87.39

Vorige sluitingsprijs

88.18

Nieuwssentiment

By Acuity

19%

81%

38 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 21:42 UTC

Winsten
Acquisities, Fusies, Overnames

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug 2025, 21:21 UTC

Winsten
Belangrijke Marktbewegers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug 2025, 20:45 UTC

Winsten

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug 2025, 23:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 aug 2025, 23:41 UTC

Marktinformatie

Nikkei May Rise on Fed Stimulus Hopes

4 aug 2025, 23:28 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 aug 2025, 23:28 UTC

Marktinformatie

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug 2025, 21:30 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 21:21 UTC

Winsten
Acquisities, Fusies, Overnames

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug 2025, 21:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 20:25 UTC

Marktinformatie

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss $938M >RIG

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug 2025, 20:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug 2025, 20:15 UTC

Winsten

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug 2025, 20:13 UTC

Winsten

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug 2025, 20:09 UTC

Winsten

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug 2025, 20:06 UTC

Winsten

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug 2025, 19:41 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug 2025, 19:28 UTC

Marktinformatie

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug 2025, 19:07 UTC

Marktinformatie

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug 2025, 18:27 UTC

Marktinformatie

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

45.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 127.73 USD  45.98%

Hoogste 165 USD

Laagste 92 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technische score

By Trading Central

87.61 / 93Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

38 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.